Aardvark Therapeutics, Inc. AARD
We take great care to ensure that the data presented and summarized in this overview for Aardvark Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in AARD
Top Purchases
Top Sells
About AARD
Insider Transactions at AARD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 11
2025
|
Tien Li Lee Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
7,000
+0.45%
|
$98,000
$14.48 P/Share
|
|
Dec 11
2025
|
Nelson Sun Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+2.69%
|
$42,000
$14.4 P/Share
|
|
Oct 15
2025
|
Bryan Jones Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+50.0%
|
$5,000
$4.24 P/Share
|
|
Oct 15
2025
|
Tien Li Lee Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,229
+0.08%
|
$4,916
$4.24 P/Share
|
|
Sep 15
2025
|
Tien Li Lee Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+0.32%
|
$90,000
$9.73 P/Share
|
|
Sep 12
2025
|
Tien Li Lee Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.33%
|
$40,000
$8.5 P/Share
|
|
Sep 11
2025
|
Tien Li Lee Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
6,000
+0.39%
|
$42,000
$7.82 P/Share
|
|
Sep 10
2025
|
Tien Li Lee Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,000
+0.59%
|
$63,000
$7.91 P/Share
|
|
Sep 09
2025
|
Nelson Sun Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
6,000
+5.38%
|
$48,000
$8.07 P/Share
|
|
Aug 28
2025
|
Tien Li Lee Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,209
+1.12%
|
$68,836
$4.24 P/Share
|
|
Feb 14
2025
|
Decheng Capital Global Life Sciences Fund Iv, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,250,000
+28.46%
|
$20,000,000
$16.0 P/Share
|
|
Feb 14
2025
|
Decheng Capital Global Life Sciences Fund Iv, L.P. |
BUY
Conversion of derivative security
|
Indirect |
2,667,299
+50.0%
|
-
|
|
Feb 14
2025
|
Jeffrey Chi |
BUY
Conversion of derivative security
|
Indirect |
133,364
+50.0%
|
-
|
|
Feb 14
2025
|
Vickers Venture Fund Vi Pte LTD |
BUY
Conversion of derivative security
|
Indirect |
2,050,902
+33.39%
|
-
|
|
Feb 14
2025
|
Tien Li Lee Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
16,542
+1.09%
|
$264,672
$16.0 P/Share
|
|
Feb 14
2025
|
Tien Li Lee Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
41,303
+2.72%
|
-
|
|
Feb 14
2025
|
Nelson Sun Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+9.13%
|
$160,000
$16.0 P/Share
|
|
Feb 14
2025
|
Nelson Sun Chief Financial Officer |
BUY
Conversion of derivative security
|
Direct |
7,001
+7.26%
|
-
|
|
Feb 14
2025
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
187,500
+15.95%
|
$3,000,000
$16.0 P/Share
|
|
Feb 14
2025
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
800,189
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
7.23M
Shares
From
12
Insiders
| Conversion of derivative security | 5.7M shares |
|---|---|
| Open market or private purchase | 1.51M shares |
| Exercise of conversion of derivative security | 19.7K shares |
Sell / Disposition
0
Shares
From
0
Insiders